Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Seikagaku Corp.: 8.8% Increase in Sales to \22,564 Mil.
June 6, 2005
- Mediceo HD: Sales Rise 29.7% to \1,665,815 Mil.
June 6, 2005
- Taiyo Pharm. Expects Over \32 Billion in Sales in FY2005
June 6, 2005
- 4 Superpowers Enhance Dominance in Wholesale Industury
June 6, 2005
- Sawai: Growth in Costs Leads to Net Loss
June 6, 2005
- TOPICS 2 articles
June 6, 2005
- Nippon Chemiphar: Sales Growth of 14.8% Driven by Generics
June 6, 2005
- Once-yearly Health Exams Becoming Norm for Housewives
June 6, 2005
- SSP: Declines in Market Prices Hit Sales and Profits
June 6, 2005
- Hokuyaku Aims at Becoming General Distributor of Healthcare Products
June 6, 2005
- OTC Drugs Should Require Explanation at Time of Sale: Subcommittee
June 6, 2005
- Rohto: Record-high Sales and Profits
June 6, 2005
- Predicting Japan Pharma in 2010: Pharma Delegate Seminar
June 6, 2005
- The Reporter's Eye: 9
June 6, 2005
- CMIC: Strong Growth in Semiannual Sales, Profits
June 6, 2005
- Toho Pharm.: Profits Plunge Despite 13.3% Rise in Sales
June 6, 2005
- Wyeth's Gemtuzumab Recommended for Approval
June 6, 2005
- Vital-Net Happy about Tie-up with Toho and Other Wholesalers
June 6, 2005
- Alfresa HD: Profits Slip Despite Growth in Sales
June 6, 2005
- Vfend and 8 Other Drugs Recommended for Approval
June 6, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…